Articles

The COVID-19 pandemic has led to the elimination of several restrictions on telehealth and infusion therapy in the home setting. In this webcast, a panel of experts discuss the short- and long-term prospects for in-home infusion for patients with cancer. What are the benefits and drawbacks? Read More ›

The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer

By Ali McBride, PharmD, MS, BCPS; Paula Anastasia, MN, RN, AOCN

Interview with the Innovators, Video

Videos

Ali McBride, PharmD, and Paula Anastasia, RN, MN, AOCN, discuss how results from germline and somatic HRD testing help provide new options for patients with ovarian cancer. This approach has been a “game changer” in clinical outcomes for these patients. Read More ›

Subcutaneous Daratumumab for Multiple Myeloma: Applying the Lessons from Clinical Trials to Clinical Practice

June 2020 Clinical Trials to Clinical Practice

Ovarian Cancer

Web Exclusives

Results from the phase 3 ARIEL3 clinical trial showed that maintenance therapy with rucaparib leads to significantly improved progression-free survival in patients with advanced ovarian cancer and non-BRCA homologous recombinant repair gene mutations. Read More ›

Niraparib plus Bevacizumab Combination Leads to Improved PFS Without Cumulative Toxicity in Advanced Ovarian Cancer

Ovarian Cancer

Web Exclusives

At the 12-month landmark analysis of the single-arm phase 2 OVARIO clinical trial, 75% of patients in the overall population of patients with newly diagnosed stage IIIB-IV ovarian cancer remained progression-free. Read More ›

Adding Olaparib to Bevacizumab as Maintenance Extends PFS in Newly Diagnosed Advanced Ovarian Cancer

Ovarian Cancer

Web Exclusives

Data from the phase 3 PAOLO-1 clinical trial showed that progression-free survival was significantly increased with olaparib plus bevacizumab as maintenance therapy. Read More ›

PARP Inhibitors in Ovarian Cancer: Choice May Depend on Treatment Setting, Mutation Status, and Side-Effect Profile

Ovarian Cancer

Web Exclusives

The approval of 3 PARP inhibitors has made it feasible to personalize therapy for patients with ovarian cancer based on their mutation status as well as other factors, including the treatment setting. Read More ›

Time to First Subsequent Therapy Longer in Patients with Advanced Ovarian Cancer Who Are Treated with Niraparib

Ovarian Cancer

Web Exclusives

The phase 3 PRIMA clinical trial demonstrated that time to first subsequent therapy was 6.6 months longer in the niraparib arm versus the placebo arm, an advantage that was maintained regardless of homologous recombination deficiency status, and the risk for second disease progression was also numerically lower in niraparib-treated patients. Read More ›

IWTI Ovarian Cancer

The Role of Genetic Testing in Patients with Ovarian Cancer

By Amina Ahmed, MD; Paula Anastasia, MN, RN, AOCN; Ali McBride, PharmD, MS, BCPS

Interview with the Innovators, Video

Videos

Amina Ahmed, MD, MS, Paula Anastasia, RN, MN, AOCN and Ali McBride, PharmD, MS, discuss the importance of genetic testing in the workup of patients with ovarian cancer, including both germline and somatic testing. The experts consider practice guidelines and results of recent clinical trials and their perspectives on the impact of genetic testing on treatment as well as clinical outcomes. Read More ›

Zepzelca New Therapy Approved for Metastatic Small-Cell Lung Cancer

FDA Updates, Lung Cancer

Web Exclusives

On June 15, 2020, the FDA accelerated the approval of lurbinectedin (Zepzelca; Jazz Pharma/Pharma Mar), an intravenous alkylating drug, for the treatment of adults with metastatic small-cell lung cancer that has progressed during or after platinum-based chemotherapy. The FDA granted lurbinectedin an orphan drug designation for this indication. Read More ›

Articles

View the Latest Issue of TON

Subscribe Today!

I'd like to receive:

Articles

Page 127 of 376

View the Latest Issue of TON

Subscribe Today!

I'd like to receive: